CytomX Therapeutics (STU:6C1) COGS-to-Revenue : 0.00 (As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is CytomX Therapeutics COGS-to-Revenue?

CytomX Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2025 was €0.0 Mil. Its Revenue for the three months ended in Mar. 2025 was €47.1 Mil.

CytomX Therapeutics's COGS to Revenue for the three months ended in Mar. 2025 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. CytomX Therapeutics's Gross Margin % for the three months ended in Mar. 2025 was N/A%.

CytomX Therapeutics COGS-to-Revenue Historical Data

The historical data trend for CytomX Therapeutics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytomX Therapeutics COGS-to-Revenue Chart

CytomX Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

CytomX Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

CytomX Therapeutics COGS-to-Revenue Calculation

CytomX Therapeutics's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	131.888
	=	0.00

CytomX Therapeutics's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	47.098
	=	0.00

CytomX Therapeutics (STU:6C1) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

CytomX Therapeutics's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 47.098
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

CytomX Therapeutics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of CytomX Therapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

CytomX Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytomX Therapeutics Inc (STU:6C1) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

CTMX:USA 6C1:Germany

Address

151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

https://www.cytomx.com

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

CytomX Therapeutics Headlines

No Headlines